Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More